Lineage Logistics Strengthens Industry-Leading Temperature-Controlled Facility Network in Europe With a Dozen Transactions in 2020
Lineage Logistics, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced the completion of twelve transactions across Europe to build on its leading global facility network. Over the past twelve months, Lineage completed strategic acquisitions across four countries that consists of twenty locations in core population and food production markets. Also included in the Company’s deal activity is a majority investment in a state-of-the art automation commissioning business located in Belgium. All acquisitions have either been successfully integrated or will be integrated in the first quarter of 2021.
Among the companies joining the Lineage team is Coldstar, Lineage’s most recent acquisition in the region which features a highly automated operation in the “Golden Triangle” of Denmark, strategically located between Jutland, Zealand and Germany. Coldstar adds nearly seven million cubic feet and over 20,000 pallet positions of cold storage capacity to the Lineage network, with more than 100 skilled and enthusiastic team members serving approximately 65% of the Danish retail market. Plans to grow this business and expand its offerings to retailers in Denmark and beyond are actively under consideration.
In addition to Coldstar, the announced transactions include:
Denmark
- Lundsøe Køl og Frys, five locations across Denmark with a substantial expansion planned for the Port of Aarhus to be completed in 2021
- Super Frost Sjaelland A/S, one location outside Copenhagen
- Kolding, one triple-net leased facility
- Kanalholmen, one triple-net leased facility
The Netherlands
- Vriescentrale Asten, one highly automated operation focused on meat processing for international export
- Frigo Group’s Heerenberg B.V. location in Heerenberg
Belgium
- F.A.I.S. - Flexible Automation Innovative Solutions – a state-of-the-art automation commissioning business that will assist Lineage in its substantial new build growth pipeline
Norway
- Larvik, one net leased facility in proximity to Larvik Harbour, Norway’s second largest container port
- Oslo, one net leased facility
- Moss Cold Storage, one operation in Moss, Norway that services the broader Norwegian market
Poland
- Pago Sp. z o.o., six locations across Poland
“In a year like 2020, which presented both challenges and opportunities, I’m proud we were able to enter new markets and continue our growth momentum around the globe,” said Greg Lehmkuhl, President and Chief Executive Officer of Lineage. “We ended the year in a strong position in the European market and more focused than ever on our purpose of transforming the food supply chain to eliminate waste and help feed the world.”
“These transactions are important to our growing European footprint and address increasing demand from customers to respond to shifting market dynamics and implement new, innovative and global supply chain solutions,” said Mike McClendon, Lineage’s President of International Operations & EVP of Network Optimization. “The strategic locations of these facilities, combined with those which offer and facilitate highly-automated operations or expansion opportunities, allow us to offer supply chain solutions that extend throughout the entire value chain.”
Following the close of these transactions, the combined Company features a global footprint that spans over 2.1 billion cubic feet of temperature-controlled capacity across over 340 facilities in 15 countries spanning North America, Europe, Asia, Australia, New Zealand, and South America.
About Lineage Logistics
Lineage is the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, its unrivaled real estate network, and its use of technology combine to promote food safety, increase distribution efficiency, advance sustainability, lessen environmental impact, and minimize supply chain waste. As a result, Lineage helps customers ranging from Fortune 500 companies to small family-owned businesses increase the efficiency and protect the integrity of their temperature-controlled supply chain. Lineage has grown its cubic feet by 60% annually since 2008 to 2.1 billion cubic feet, making it the largest global temperature-controlled industrial REIT. In recognition of the company’s leading innovations, Lineage was recognized as the No 1. Data Science company on Fast Company’s Annual list of The World’s Most Innovative Companies in 2019, in addition to ranking 23rd overall in an evaluation of thousands of companies worldwide. (www.lineagelogistics.com)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005802/en/
Contact information
Lineage Logistics
Megan Hendricksen
949.247.5172
mhendricksen@lineagelogistics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage20.10.2025 09:00:00 EEST | Press release
Lazard, Inc. (NYSE: LAZ) today announced the appointment of Edouard Panié as Managing Director and Co-Head of the European Financial Sponsors Coverage. He will report to Klaus H. Hessberger, Global Co-Head and Head of Europe for Lazard’s Financial Sponsors Group, to further strengthen the firm’s presence and partnerships with financial sponsors across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019307537/en/ Edouard Panié Mr. Panié joins from Goldman Sachs, where he was a Managing Director for nearly two decades, advising on more than 60 landmark M&A, debt, and equity transactions for leading alternative asset managers in private equity, growth equity, and infrastructure, as well as entrepreneurs, families, and corporates. “Private capital is playing an increasingly pivotal role in shaping industries and driving growth. Edouard’s extensive experience and relationships will strengthen Lazard’s ability to pro
Lone Star Announces Sale of Xella to Holcim20.10.2025 07:40:00 EEST | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund X, LP of a binding agreement to sell Xella Group (“Xella”), a leading provider of walling solutions, to Holcim, the leading partner for sustainable construction. The transaction values Xella at approximately €1.85 billion. Headquartered in Duisburg, Germany, Xella is a European provider of efficient and sustainable walling solutions for the entire house shell, operating brands such as Ytong, Silka, Hebel and Multipor. The company employs more than 4,000 team members. In partnership with Lone Star, Xella has taken significant strides in recent years to optimize its offering by strategically focusing the business on walling solutions, while also enhancing its commercial and digital capabilities. Under Lone Star’s stewardship, Xella has also continued to progress its sustainability initiatives. Today, the business stands as a market leader in its sector with a strong reputation for a people-first c
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products20.10.2025 07:00:00 EEST | Press release
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/ MOSS!MODULARITY Injection Screw MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.: Improved visualisation and access to the surgical working space; Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads; Increased surgic
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom